{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:51:29Z","timestamp":1761519089410},"reference-count":52,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,6,1]]},"abstract":"<jats:p>Raloxifene is the first selective estrogen receptor modulator registered for the prevention and treatment of postmenopausal osteoporosis. In addition to direct effects on bone cells, estrogen and raloxifene may act indirectly via changes in hormonal homeostasis. However, the menopause-related decrease in serum insulin-like growth factor I (IGF-I) and the increase in insulin or glucose are not always reversed by estrogen replacement. Especially orally administered estrogen was reported to decrease serum IGF-I levels. Understanding the effects of estrogens and raloxifene on the GH-IGF axis and insulin-glucose homeostasis are important because of their link to bone metabolism and cardiovascular health.<\/jats:p>\n               <jats:p>We investigated the effects of raloxifene on the GH-IGF-I axis and insulin-glucose homeostasis in a cross-sectional study in the third year of the Multiple Outcomes of Raloxifene Evaluation trial, a double blind, placebo-controlled, prospective study in postmenopausal women with osteoporosis (T-score of \u22122.5 or less or at least two moderate vertebral fractures). Patients with diabetes mellitus were excluded from this additional study. A fasting blood sample was obtained (0 h), and women received an sc injection of 0.05 mg recombinant human GH (Humatrope)\/kg BW. The second blood sample was obtained 24 h later (24 h). GH, IGF-I, IGF-binding protein-3 (IGFBP-3), insulin, and glucose were measured. Group characteristics were tested by nonparametric ANOVA. The dose-response to raloxifene was tested by linear regression models, with age and body mass as covariates.<\/jats:p>\n               <jats:p>Seven women were taking placebo, 16 were taking raloxifene (60 mg\/day), and 9 were taking raloxifene (120 mg\/day). Patients from the 60 mg raloxifene group were the oldest (mean \u00b1 sd, 64.4 \u00b1 4.2 vs. 69.3 \u00b1 6.9 and 63.3 \u00b1 5.9 yr for placebo, 60 mg\/day raloxifene, and 120 mg\/day raloxifene, respectively; P = 0.05). Compared with placebo users, patients taking raloxifene had higher body mass index (24.7\u00b1 1.7 vs. 25.0 \u00b1 3.1 and 28.8 \u00b1 5.8 kg\/m2; P = 0.03). At 0 h, raloxifene use was associated with lower IGF-I\/IGFBP-3 ratio (4.3\u00b1 0.7 vs. 2.9 \u00b1 0.7 and 3.0 \u00b1 0.7 nmol\/mg; P = 0.001) and insulin\/glucose ratio (13.7 \u00b1 5.2 vs. 11.9 \u00b1 5.9 and 9.5 \u00b1 2.3 pmol\/mmol; P = 0.04). Similarly, raloxifene use was associated with lower IGF-I\/IGFBP-3 and insulin\/glucose ratios at 24 h (P = 0.01 and 0.07). Glucose, GH, and IGFBP-3 levels were similar among the groups (0.12 &amp;lt; P &amp;lt; 0.67).<\/jats:p>\n               <jats:p>In conclusion, raloxifene use is associated with decreased serum IGF levels and insulin\/glucose ratio before and 24 h after one rhGH injection in nondiabetic postmenopausal women with osteoporosis. Therefore, raloxifene may decrease liver sensitivity to GH. Other explanations are increased clearance or increased tissue sensitivity to IGF-I or insulin. The raloxifene-induced increases in bone mineral density do not appear to be mediated by reversing the age- and menopause-related decreases in IGF-I levels. The results of this small cross-sectional study need confirmation by longitudinal studies.<\/jats:p>","DOI":"10.1210\/jcem.86.6.7549","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T17:06:53Z","timestamp":1389200813000},"page":"2763-2768","source":"Crossref","is-referenced-by-count":19,"title":["Effects of the Selective Estrogen Receptor Modulator, Raloxifene, on the Somatotropic Axis and Insulin-Glucose Homeostasis"],"prefix":"10.1210","volume":"86","author":[{"given":"Anna M.","family":"Oleksik","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Academic Hospital Vrije Universiteit (A.M.O., N.P., G.A., C.P.-S., P.L.), 1007 MB Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tu","family":"Duong","sequence":"additional","affiliation":[{"name":"Prevention Sciences Group, University of California (T.D.), San Francisco, California 94105"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolette","family":"Pliester","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Academic Hospital Vrije Universiteit (A.M.O., N.P., G.A., C.P.-S., P.L.), 1007 MB Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greetje","family":"Asma","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Academic Hospital Vrije Universiteit (A.M.O., N.P., G.A., C.P.-S., P.L.), 1007 MB Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrie","family":"Popp-Snijders","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Academic Hospital Vrije Universiteit (A.M.O., N.P., G.A., C.P.-S., P.L.), 1007 MB Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Lips","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Academic Hospital Vrije Universiteit (A.M.O., N.P., G.A., C.P.-S., P.L.), 1007 MB Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071621400925100_R1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene.","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"2020071621400925100_R2","first-page":"77","article-title":"The Bedford survey ten-year mortality rates in newly diagnosed diabetics, borderline diabetics, and normoglycaemic controls, and risk indices for coronary heart disease in borderline diabetics.","volume":"22","author":"Jarret","year":"1982","journal-title":"Diabetologia"},{"key":"2020071621400925100_R3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/diacare.13.6.631","article-title":"Insulin and atheroma: 20-year perspective.","volume":"13","year":"1990","journal-title":"Diabetes Care"},{"key":"2020071621400925100_R4","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1359\/jbmr.1998.13.8.1343","article-title":"Gender differences in insulin-like growth factor and bone mineral density: the Rancho Bernardo Study.","volume":"13","author":"Barrett-Connor","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2020071621400925100_R5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01352006","article-title":"Effects of estrogen deficiency on IGF-1 plasma levels: relationship with bone mineral density in perimenopausal women.","volume":"53","author":"Romagnoli","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"2020071621400925100_R6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S8756-3282(97)00150-6","article-title":"Insulin-like growth factors and osteoporosis.","volume":"21","year":"1997","journal-title":"Bone"},{"key":"2020071621400925100_R7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1210\/jcem-64-1-51","article-title":"Effects of sex and age on 24-hour profile of growth hormone secretion in men: importance of endogenous estradiol concentrations.","volume":"64","author":"Ho","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621400925100_R8","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1126\/science.125.3253.884","article-title":"Metabolic effects of human and monkey growth hormone in man.","volume":"125","author":"Beck","year":"1957","journal-title":"Science"},{"key":"2020071621400925100_R9"},{"key":"2020071621400925100_R10","author":"Kaufman","year":"1996"},{"key":"2020071621400925100_R11","author":"Blum","year":"1996"},{"key":"2020071621400925100_R12","first-page":"243","volume":"251","author":"Bo\u0308ni-Schnetzler","year":"1989"},{"key":"2020071621400925100_R13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00505182","article-title":"Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man.","volume":"32","author":"M\u00f8ller","year":"1989","journal-title":"Diabetologia"},{"key":"2020071621400925100_R14","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1172\/JCI116828","article-title":"Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and improves insulin sensitivity in humans.","volume":"92","author":"Hussain","year":"1993","journal-title":"J Clin Invest"},{"key":"2020071621400925100_R15","first-page":"804","article-title":"Insulin-like growth factor I inhibits glucose stimulated insulin secretion but does not impair glucose metabolism in normal humans.","volume":"76","author":"Rennert","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621400925100_R16","first-page":"E130","article-title":"Diverse effects of insulin-like growth factor I on glucose, lipid, and amino-acids","volume":"262","author":"Boulware","year":"1992","journal-title":"Am J Physiol"},{"key":"2020071621400925100_R17","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1172\/JCI116480","article-title":"A low-dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.","volume":"91","author":"Hartman","year":"1993","journal-title":"J Clin Invest"},{"key":"2020071621400925100_R18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2362.1993.tb00792.x","article-title":"The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women.","volume":"23","author":"Walton","year":"1993","journal-title":"Eur J Clin Invest"},{"key":"2020071621400925100_R19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1042\/cs0830489","article-title":"Ageing and the response of plasma insulin, glucose and C-peptide concentration to intravenous glucose in postmenopausal women.","volume":"83","author":"Proudler","year":"1992","journal-title":"Clin Sci"},{"key":"2020071621400925100_R20"},{"key":"2020071621400925100_R21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/jbmr.5650070711","article-title":"Impact of short-term estrogen administration on growth hormone secretion and activation: distinct route-dependent effects on connective and bone tissue metabolism.","volume":"7","author":"Ho","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2020071621400925100_R22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem-72-2-374","article-title":"Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women.","volume":"72","author":"Weissberger","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621400925100_R23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/BF03348801","article-title":"Transdermal 17\u03b2-estradiol combined with oral progesteron increases plasma levels of insulin-like growth factor I in postmenopausal women.","volume":"15","author":"Slowinska-Srzednicka","year":"1992","journal-title":"J Endocrinol Invest"},{"key":"2020071621400925100_R24","first-page":"1783","article-title":"A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women.","volume":"80","author":"O\u2019Sullivan","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621400925100_R25","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1210\/jcem.84.7.5836","article-title":"The effect of estradiol\/progestagen preparation on insulin sensitivity in healthy postmenopausal women.","volume":"84","author":"Duncan","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621400925100_R26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-2007-1001671","article-title":"The insulin-like growth factor I generation test: resistance to growth hormone with ageing and estrogen replacement therapy.","volume":"26","author":"Lieberman","year":"1994","journal-title":"Horm Metab Res"},{"key":"2020071621400925100_R27","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1210\/jcem-63-2-424","article-title":"Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effects of physiological estrogen replacement.","volume":"63","author":"Dawson-Hughes","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621400925100_R28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2265.1993.tb02410.x","article-title":"Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women.","volume":"39","author":"Kelly","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071621400925100_R29","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0015-0282(16)57181-7","article-title":"The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women.","volume":"62","author":"Lindheim","year":"1994","journal-title":"Fertil Steril"},{"key":"2020071621400925100_R30","first-page":"987","article-title":"Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women.","volume":"84","author":"Lobo","year":"1994","journal-title":"Obstet Gynecol"},{"key":"2020071621400925100_R31","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2337\/diacare.21.10.1589","article-title":"Effects of postmenopausal hormone therapy on glucose and insulin concentrations.","volume":"21","author":"Espeland","year":"1998","journal-title":"Diabetes Care"},{"key":"2020071621400925100_R32","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effects of raloxifene on risk of breast cancer in postmenopausal women.","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"2020071621400925100_R33","first-page":"2250","article-title":"Both oral and transdermal estrogen replacement increase GH release in postmenopausal women\u2013a clinical research center study.","volume":"81","author":"Friend","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621400925100_R34","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/jnci\/82.21.1693","article-title":"Effects of tamoxifen on serum insulinelike growth factor levels in stage I breast cancer patients.","volume":"82","author":"Pollak","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"2020071621400925100_R35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/eje.0.1390309","article-title":"Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-1 serum levels in women with breast cancer.","volume":"139","author":"Corsello","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"2020071621400925100_R36","first-page":"2848","article-title":"Effects of oral versus transdermal estrogen on the growth hormone\/insulin-like growth factor axis in younger and older postmenopausal women: a clinical research center study.","volume":"81","author":"Bellantoni","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621400925100_R37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000184762","article-title":"Sex steroid regulation of growth hormone secretion and action.","volume":"45","author":"Ho","year":"1996","journal-title":"Horm Res"},{"key":"2020071621400925100_R38","first-page":"2037","article-title":"Regulation of insulin-like growth factor I receptor expression by the pure anti-estrogen ICI 182780.","volume":"2","author":"Huynh","year":"1996","journal-title":"Clin Cancer Res"},{"key":"2020071621400925100_R39","first-page":"35","article-title":"Interactions between the oestrogen and insulin-like growth factor signalling pathways in the control of breast epithelial cell proliferation.","volume":"63","author":"Westley","year":"1998","journal-title":"Biochem Soc Symp"},{"key":"2020071621400925100_R40","doi-asserted-by":"crossref","first-page":"B117","DOI":"10.1093\/gerona\/53A.2.B117","article-title":"Growth hormone in postmenopausal women after long-term oral estrogen replacement therapy","volume":"53A","author":"Moe","year":"1998","journal-title":"J Gerontol."},{"key":"2020071621400925100_R41","doi-asserted-by":"crossref","first-page":"M176","DOI":"10.1093\/gerona\/53A.3.M176","article-title":"Serum levels of insulin-like growth factor-I are related to age and not to body composition in healthy women and men","volume":"53","author":"O\u2019Connor","year":"1998","journal-title":"J Gerontol."},{"key":"2020071621400925100_R42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0960-0760(91)90179-9","article-title":"The role of sexual steroids in the modulation of growth hormone (GH) secretion in humans.","volume":"40","author":"Devesa","year":"1991","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2020071621400925100_R43","first-page":"R1351","article-title":"Actions of estrogen on pulsatile, nyctohemeral, and entropic models of growth hormone secretion","volume":"45","author":"Shah","year":"1999","journal-title":"Am J Physiol."},{"key":"2020071621400925100_R44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1210\/jcem-72-1-172","article-title":"Effects of progestin-opposed transdermal estrogen administration on GH and IGF-I in postmenopausal women of different ages.","volume":"72","author":"Bellantoni","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621400925100_R45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1210\/jcem-72-1-51","article-title":"Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatropism of obesity in man.","volume":"72","author":"Veldhuis","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621400925100_R46","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0015-0282(16)56218-9","article-title":"A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin.","volume":"60","author":"Lindheim","year":"1993","journal-title":"Fertil Steril"},{"key":"2020071621400925100_R47","first-page":"1396","article-title":"Effects of low dosis of transdermal 17\u03b2-estradiol on carbohydrate metabolism in postmenopausal women.","volume":"74","author":"Cagnacci","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621400925100_R48","first-page":"265","article-title":"Induction of insulin resistance by androgens and estrogens.","volume":"79","author":"Polderman","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621400925100_R49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2337\/diacare.19.4.333","article-title":"Factors associated with glucose and insulin in healthy postmenopausal women.","volume":"19","author":"Barrett-Connor","year":"1996","journal-title":"Diabets Care"},{"key":"2020071621400925100_R50","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/oxfordjournals.aje.a116768","article-title":"How good a marker is insulin level for insulin resistance?","volume":"137","year":"1993","journal-title":"Am J Epidemiol"},{"key":"2020071621400925100_R51","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"2020071621400925100_R52","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1046\/j.1365-2265.1998.00613.x","article-title":"The IGF-I response to very low rhGH doses is preserved in human ageing.","volume":"49","author":"Arvat","year":"1998","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/86\/6\/2763\/9169096\/jcem2763.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/86\/6\/2763\/9169096\/jcem2763.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T09:22:05Z","timestamp":1594977725000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/86\/6\/2763\/2849148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6,1]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcem.86.6.7549","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6,1]]}}}